{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:36:46Z","timestamp":1782193006496,"version":"3.54.5"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1616,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiotensin-converting enzyme inhibitors (ACEIs) are commonly prescribed in dogs, but the ideal dosage is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>In dogs with cardiac disease, a dose-response relationship exists for ACEIs with respect to long-term outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>One hundred forty-four dogs with cardiac disease, 63 with current or prior congestive heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective medical record review. Cox proportional hazards models were used to determine variables associated with 2-year survival or survival from first-onset congestive heart failure (CHF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median initial ACEI dosage was 0.84 (interquartile range [IQR], 0.56-0.98) mg\/kg\/day, and 108\/144 (75%) of dogs received q12h dosing. No clinically relevant changes in renal function test results, serum electrolyte concentrations, or blood pressure occurred between initial prescription of ACEI and first reevaluation (median, 14\u2009days later). In univariable analysis, higher ACEI dose was associated with increased survival from first-onset CHF (P\u00a0=\u2009.005), and within the subgroup of dogs in CHF at the time of ACEI prescription, higher ACEI dose was associated with improved survival at 2\u2009years (P\u00a0=\u2009.04). In multivariable analysis, q12h dose frequency of ACEI (hazard ratio [HR], 0.30; 95% CI, 0.10-0.88; P\u00a0=\u2009.03) and higher serum potassium concentration at visit 1 (HR, 0.39; 95% CI, 0.16-0.97; P\u00a0=\u2009.04) were predictive of 2-year survival. The ACEIs were well-tolerated, with only 8\/144 (5.6%) dogs having ACEI dose decreased or discontinued because of adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Twice daily dose frequency might optimize the cardioprotective benefit of ACEIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16236","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T06:06:55Z","timestamp":1628834815000},"page":"2102-2111","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9153-7916","authenticated-orcid":false,"given":"Jessica L.","family":"Ward","sequence":"first","affiliation":[{"name":"Iowa State University Department of Veterinary Clinical Sciences, , Ames, Iowa,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yu","family":"Chou","sequence":"additional","affiliation":[{"name":"Iowa State University Department of Veterinary Clinical Sciences, , Ames, Iowa,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingnan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Iowa State University Department of Statistics, , Ames, Iowa,","place":["USA"]},{"name":"SMART Pharmacology, Iowa State University Department of Biomedical Sciences, , Ames, Iowa,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin S.","family":"Dorman","sequence":"additional","affiliation":[{"name":"Iowa State University Department of Statistics, , Ames, Iowa,","place":["USA"]},{"name":"Development and Cell Biology, Iowa State University Department of Genetics, , Ames, Iowa,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Mochel","sequence":"additional","affiliation":[{"name":"SMART Pharmacology, Iowa State University Department of Biomedical Sciences, , Ames, Iowa,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2026020303473996800_jvim16236-bib-0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group","volume":"9","author":"COVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial","volume":"1","author":"BENCH (BENazepril in Canine Heart disease) Study Group","year":"1999","journal-title":"J Vet Cardiol"},{"key":"2026020303473996800_jvim16236-bib-0003","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/euhj.1998.1098","article-title":"Long-term survival in severe heart failure in patients treated with enalapril: ten year follow-up of CONSENSUS I","volume":"20","author":"Swedberg","year":"1999","journal-title":"Eur Heart J"},{"key":"2026020303473996800_jvim16236-bib-0004","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2885.2004.00614.x","article-title":"Angiotensin-converting enzyme inhibitors in the therapy of renal diseases","volume":"27","author":"Lefebvre","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020303473996800_jvim16236-bib-0006","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/jvim.15331","article-title":"ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats","volume":"32","author":"Acierno","year":"2018","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cvsm.2016.06.009","article-title":"Management of proteinuria in dogs and cats with chronic kidney disease","volume":"46","author":"Vaden","year":"2016","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020303473996800_jvim16236-bib-0008","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jvim.14726","article-title":"Effects of benazepril on survival of dogs with chronic kidney disease: a multicenter, randomized, blinded, placebo-controlled clinical trial","volume":"31","author":"King","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0009","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/jvim.12230","article-title":"Consensus recommendations for standard therapy of glomerular disease in dogs","volume":"27","author":"IRIS Canine GN Study Group Standard Therapy Subgroup","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0010","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","article-title":"Chemistry and pharmacology of angiotensin-converting enzyme inhibitors","volume":"21","author":"Regulski","year":"2014","journal-title":"Curr Pharm Des"},{"key":"2026020303473996800_jvim16236-bib-0011","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2885.2004.00601.x","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors","volume":"27","author":"Toutain","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020303473996800_jvim16236-bib-0012","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2460\/ajvr.1995.56.12.1620","article-title":"Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs","volume":"56","author":"King","year":"1995","journal-title":"Am J Vet Res"},{"key":"2026020303473996800_jvim16236-bib-0013","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0022-3565(24)35393-5","article-title":"Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic\/pharmacodynamic modeling approach","volume":"292","author":"Toutain","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2026020303473996800_jvim16236-bib-0014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1939-1676.1998.tb02101.x","article-title":"Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles","volume":"12","author":"Hamlin","year":"1998","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"106","author":"van de Wal","year":"2006","journal-title":"Int J Cardiol"},{"key":"2026020303473996800_jvim16236-bib-0016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2885.2012.01406.x","article-title":"Capturing the dynamics of systemic renin-angiotensin-aldosterone system (RAAS) peptides heightens the understanding of the effect of benazepril in dogs","volume":"36","author":"Mochel","year":"2013","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020303473996800_jvim16236-bib-0017","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s11095-014-1587-9","article-title":"Pharmacokinetic\/pharmacodynamic modeling of renin-angiotensin aldosterone biomarkers following angiotensin-converting enzyme (ACE) inhibition therapy with benazepril in dogs","volume":"32","author":"Mochel","year":"2015","journal-title":"Pharm Res"},{"key":"2026020303473996800_jvim16236-bib-0018","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/07420528.2014.897711","article-title":"Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs","volume":"31","author":"Mochel","year":"2014","journal-title":"Chronobiol Int"},{"key":"2026020303473996800_jvim16236-bib-0019","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3109\/07420528.2013.807275","article-title":"Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology","volume":"30","author":"Mochel","year":"2013","journal-title":"Chronobiol Int"},{"key":"2026020303473996800_jvim16236-bib-0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/112_2015_27","article-title":"Chronobiology and pharmacologic modulation of the renin-andiogensin-aldosterone system in dogs: what have we learned?","volume":"169","author":"Mochel","year":"2015","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"2026020303473996800_jvim16236-bib-0021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1939-1676.1995.tb01074.x","article-title":"Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of enalapril study","volume":"9","author":"The IMPROVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0022","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303473996800_jvim16236-bib-0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1939-1676.2002.tb01610.x","article-title":"Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation","volume":"16","author":"Kvart","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0024","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2460\/javma.231.7.1061","article-title":"Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency","volume":"231","author":"Atkins","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303473996800_jvim16236-bib-0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jvc.2019.12.002","article-title":"DELay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: the DELAY study","volume":"27","author":"Borgarelli","year":"2020","journal-title":"J Vet Cardiol"},{"key":"2026020303473996800_jvim16236-bib-0026","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0027","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1939-1676.2009.0346.x","article-title":"Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman pinschers","volume":"23","author":"O'Grady","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/07420528.2012.709448","article-title":"Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation","volume":"30","author":"Hermida","year":"2013","journal-title":"Chronobiol Int"},{"key":"2026020303473996800_jvim16236-bib-0029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/jhh.2014.1","article-title":"Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction","volume":"28","author":"Hermida","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2026020303473996800_jvim16236-bib-0030","first-page":"4565-4576","article-title":"Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial","volume":"41","author":"Hermida","year":"2019","journal-title":"Eur Heart J"},{"key":"2026020303473996800_jvim16236-bib-0031","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/jvim.15251","article-title":"Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom","volume":"33","author":"Mattin","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0032","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/jvim.15390","article-title":"Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom","volume":"33","author":"Mattin","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0033","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1939-1676.1997.tb00474.x","article-title":"Signalment, survival, and prognostic factors in Doberman pinschers with end-stage cardiomyopathy","volume":"11","author":"Calvert","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0034","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2460\/javma.1997.210.04.505","article-title":"Clinical and pathologic findings in Doberman pinschers with occult cardiomyopathy that died suddenly or developed congestive heart failure: 54 cases (1984-1991)","volume":"210","author":"Calvert","year":"1997","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303473996800_jvim16236-bib-0035","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/eurheartj\/ehm091","article-title":"A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure","volume":"28","author":"Ahmed","year":"2007","journal-title":"Eur Heart J"},{"key":"2026020303473996800_jvim16236-bib-0036","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ajh\/hpy101","article-title":"Serum potassium and cardiovascular events in heart failure with preserved left ventricular ejection fraction patients","volume":"31","author":"Nishihara","year":"2018","journal-title":"Am J Hypertens"},{"key":"2026020303473996800_jvim16236-bib-0037","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1939-1676.2007.tb03016.x","article-title":"Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study","volume":"21","author":"Chetboul","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303473996800_jvim16236-bib-0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jvc.2016.05.001","article-title":"Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin\u2013angiotensin\u2013aldosterone system activation in normal dogs","volume":"18","author":"Sakatani","year":"2016","journal-title":"J Vet Cardiol"},{"key":"2026020303473996800_jvim16236-bib-0039","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2460\/javma.2002.221.654","article-title":"Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation","volume":"221","author":"Atkins","year":"2002","journal-title":"J Am Vet Med Assoc"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16236","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/5\/2102\/66673007\/jvim16236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/5\/2102\/66673007\/jvim16236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:48:03Z","timestamp":1770108483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/5\/2102\/8448749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16236","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"2021-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}